Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | RBM5 |
| Gene Name: | RBM5 |
| Protein Full Name: | RNA-binding protein 5 |
| Alias: | G15; H37; LUCA15; RMB5; RNA binding motif protein 5 |
| Mass (Da): | 92154 |
| Number AA: | 815 |
| UniProt ID: | P52756 |
| Locus ID: | 10181 |
| COSMIC ID: | RBM5 |
| Gene location on chromosome: | 3p21.3 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19813 |
| Percent of cancer specimens with mutations: | 0.64 |
| Normal role description: | RBM5 is an RNA-binding protein found to be a component of the spliceosome A complex required for regulating alternative splicing of transcribed mRNA. RBM5 is thought to have a role in regulating apoptosis as a tumour suppressor protein. Fas-mediated apoptosis was prevented in RBM5 knockdown models. RBM5 expression can be correlated with increased expression of tumour suppressor genes, Stat5b, annexin I, BMP5 while downregulating oncogenes Pim-1, ITPA and AIB1. Downregulation of RBM5 is observed in breast cancer, human schwannomas and lung cancer, and has been identified as a gene marker for highly metastatic solid tumours. Mutations in RBM5 are rarely observed however in cancer. |